Health Catalyst, Inc. reports developments tied to healthcare intelligence, data and analytics technology, and professional services for healthcare organizations. Company updates commonly cover operating results, revenue and Adjusted EBITDA guidance, and the use of AI-driven technology and domain expertise to support health systems across cost, clinical, and consumer performance.
Recurring news also includes leadership and board governance changes, shareholder-related board appointments, investor conference participation, and updates on strategic focus areas for its healthcare data platform, analytics applications, implementation, advisory, outsourcing, and improvement services.
Health Catalyst (Nasdaq: HCAT) reported third-quarter 2026 revenue of $56.283 million, down year over year, while recording a net profit. Revenue fell 26%, and gross margin declined to 31% from 39%. Net income was $40.496 million, or $0.53 per diluted share, versus a $22.229 million loss a year earlier, largely driven by a $65.889 million gain on the Vitalware business sale.
The Vitalware divestiture closed July 31, 2026. The company attributed operating declines primarily to the sale and difficulties migrating from DOS to Ignite, partly offset by cost reductions. Adjusted EBITDA, a non-GAAP earnings measure, fell 94% to $779,000. Health Catalyst reaffirmed its 2026 outlook for revenue of $246 million to $249 million and adjusted EBITDA of $18 million to $18.5 million. At September 30, no debt remained on the balance sheet, versus current and long-term debt at December 31, 2025.
Health Catalyst (HCAT) will release its third quarter 2026 operating results after market close on November 5, 2026. The company will host a conference call to review the results at 5:00 pm ET that day. A live webcast and a replay will be available on its investor relations website, with the replay accessible for approximately 90 days.
Health Catalyst (HCAT) granted 2,747,385 restricted stock units (RSUs) to new Chief Executive Officer and President Simeon Kohl on September 14, 2026 under its 2026 Employment Inducement Incentive Plan, structured to comply with Nasdaq Listing Rule 5635(c)(4).
Of these RSUs, 915,975 are scheduled to vest on September 14, 2027, with the remaining units vesting in eight approximately equal quarterly installments, each subject to Mr. Kohl’s continued employment on the applicable vesting date. The awards are governed by the Inducement Plan and an RSU agreement and are reserved for individuals who are newly hired or re-hired after a bona fide break in service as material inducements to employment. On September 11 and 14, 2026, Mr. Kohl also acquired a total of 59,000 shares of Health Catalyst common stock in open market purchases at a weighted average price of $1.787188 per share.
Health Catalyst (HCAT) appointed Tami Reller to its board of directors, effective October 1, 2026.
Reller will serve as audit committee chair and as a member of the compensation committee from that date. Her appointment follows the naming of Simeon Kohl as chief executive officer and president, effective September 14, 2026, as the company pursues its next phase as an AI-focused healthcare intelligence provider built on 18 years of results and $2.8 billion in documented outcomes.
Reller brings executive leadership experience from Duly Health and Care, Microsoft, and multiple UnitedHealth Group subsidiaries, along with public-company board roles at SPS Commerce and former Avalara, plus service on nonprofit healthcare boards.
Health Catalyst (HCAT) appointed Simeon Kohl as Chief Executive Officer, President, and Board member, effective September 14, 2026.
Kohl previously served as CEO of public healthcare company Performant Healthcare, which he led through a strategic and operational transformation ending in its sale to Machinify for approximately $670 million. He brings more than 20 years of healthcare experience across operations, growth, and public-company leadership.
Current CEO and President Ben Albert will become Chief Business Officer and leave the Board on September 13, 2026, continuing to work closely with Kohl on strategic priorities. Under Albert’s leadership, Health Catalyst sharpened its focus on AI-forward healthcare intelligence, divested Vitalware, and used proceeds to retire an approximately $160 million credit facility, which the company states strengthened its balance sheet. Health Catalyst cites $2.8 billion in documented outcomes supported by its proprietary data.
Health Catalyst (Nasdaq: HCAT) announced that senior management will participate in the 2026 Wells Fargo Healthcare Conference in Boston on Wednesday, September 9, 2026 and Thursday, September 10, 2026. The company highlights its healthcare intelligence platform, AI-driven technology, and $2.8 billion in documented outcomes supporting health system performance improvement.
Health Catalyst (Nasdaq: HCAT) reported second quarter 2026 revenue of $70.5 million, down 13% year over year, with GAAP gross margin of 40% versus 38% a year ago. Net loss was $40.5 million, roughly flat year over year, while adjusted EBITDA was $9.9 million, up 6%. According to the company, results exceeded the high end of prior revenue guidance and the midpoint of adjusted EBITDA guidance.
The company recently closed the Vitalware divestiture and fully repaid its credit facility debt, which management said strengthens the balance sheet and increases flexibility. As of June 30, 2026, cash and cash equivalents were $60.6 million with $42.9 million in short-term investments, and operating cash flow for the first half was $18.8 million. Second quarter results included a $27.0 million goodwill impairment, contributing to a six‑month net loss of $151.6 million and a decline in stockholders’ equity to $100.8 million.
Health Catalyst (Nasdaq: HCAT) has closed the sale of its Vitalware business, conducted through Vitalware, LLC, to Med-Metrix, LLC for $147 million in cash, subject to customary adjustments. The transaction closed on July 31, 2026.
Health Catalyst used the net cash proceeds plus cash on hand to fully repay and terminate all obligations under its credit facility, eliminating about $19 million in annual GAAP interest expense based on the first half of 2026. According to Health Catalyst, the strengthened balance sheet will support focused investment in its healthcare intelligence strategy and AI-driven products, leveraging $2.8 billion in documented outcomes across more than 380 client improvement case studies to help health systems improve cost, clinical quality, and consumer performance.
Health Catalyst (Nasdaq: HCAT) will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close, and host a conference call to review the results at 5:00 p.m. ET, with live and replay webcasts available on its investor relations site.
Health Catalyst (Nasdaq: HCAT) announced that senior management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference.
Chief Executive Officer Ben Albert will join a panel titled “AI ROI in Healthcare: Real vs Hype Debate” on June 24, 2026 at 3:30pm ET.